RGS RGS Healthcare Solutions

Partner-led manufacturers

Your partners hold the authorisations. You still need to see the market

Manufacturers that out-license or supply through partners rarely see the tenders, registrations or supplier choices that decide their volume. RGS brings these into view: which tenders your partners are fighting, which authorisations sit under their names, and how much of each partner is still supplied by you.

The challenge

What makes tendering hard for partner-led manufacturers

01

The tender is your partner's, the volume is yours

Partners bid, but the outcome decides your production plan. Without tender visibility you forecast blind.

02

Registrations sit under other names

Authorisations are held by partners in many markets, so a second supplier or a new market can go unnoticed for months.

03

Switching happens quietly

A partner moving volume to another manufacturer shows up in your sales only after the contract has changed.

What you get

How RGS helps

Discovery, award intelligence and pricing guidance on one data layer, with our team available when you need analysis or hands-on support.

Used by business development and licensing directors, partner account managers, tender sales managers, supply and production planners.

  • Tender visibility per partner, product and country, routed to each account owner
  • Authorisation tracking across your partners' registrations
  • Supply share per partner, with a monthly list of what moved
  • Price evidence to support partner negotiations
  • Tender-calendar-driven production forecasts
  • Partners' own tender names matched to the official tender

Case study

Dutch generics manufacturer

Giving a manufacturer's partners the prices to compete

A Dutch generics manufacturer that sells through distribution partners and does not bid itself had little visibility of the tenders its partners were fighting.

Partner enablement
We gave partners tender-by-tender intelligence on upcoming rounds, likely competitors and price levels.
Margin visibility
We estimated the margins partners earned on the manufacturer's products, so pricing could be set per partner.
Better forecasts
Knowing which tenders were coming improved production planning and reduced over- and under-supply.

Results

Higher

Partner win rates on the manufacturer's molecules

Data-led

Commercial negotiations with each partner

All case studies

Also for: Generics and biosimilars, Branded pharma, MedTech

Questions

Questions teams ask us

Our partners refer to tenders by their own names. Can RGS match them?

Yes. Partners often say 'GWQ 35' or 'AOK 22' instead of the official title. RGS keeps those names as aliases on the actual tender, so sales, partners and planning talk about the same round.

Which partner tenders matter most for our volume?

RGS ranks each partner's upcoming rounds by the volume and value at stake for your products, so account managers know where to support the bid first.

More questions? See all questions, how pricing works, the platform and integrations or who is behind RGS.

See what the tender data says about your portfolio

We load your products and markets before the session, so the conversation starts with your own tenders.